A noninvasive DNA blood test can identify metastatic castration-resistant prostate cancer (mCRPC) patients who are most likely to benefit from ²²³Ra radiopharmaceutical therapy and monitor their progress throughout treatment, according to new research published in the July issue of The Journal of Nuclear Medicine. Incorporating this new approach to DNA profiling into clinical practice has the potential to refine patient selection, enable early detection of treatment resistance, and optimize personalized management for prostate cancer patients.

Dr. Alex Zhavoronkov, Founder and Co-CEO of Insilico Medicine, and Dr. Feng Ren, Co-CEO and Chief Scientific Officer, have been invited to attend the inaugural China Pioneer Innovative Drug Global Congress (CPIC 2026), which will grandly convene at the National Exhibition and Convention Center (Shanghai) from July 22 to 24. During this premier event, the two industry leaders will appear at several high-profile forums to deliver keynote speeches, sharing deep insights on how cutting-edge AI combines with "China Speed" to decode the mysteries of life and reshape the global drug R&D landscape.

A study by the University of Barcelona has identified nearly 20 genes that could contribute to some people being more susceptible to depression, anxiety and traits such as irritability and neuroticism. These genes are regulated by the RBFOX1 gene, which acts as the central hub of a genetic network linked to several key processes in brain function. According to the researchers, this genetic overlap between different disorders and traits could help explain why they often appear together in the same person.

Researchers at QST have found that tau buildup in progressive supranuclear palsy may affect brain networks involved in thinking and behaviour. The findings suggest that symptoms appear to arise not only from where tau accumulates in the brain, but also from how those affected areas are connected to distant brain regions.

Millions of people worldwide live with periodontitis, a chronic gum disease that can progressively destroy the tissues and bone supporting the teeth despite conventional treatment. Seeking a more comprehensive solution, researchers developed a novel DNA-based nanoplatform designed to deliver multiple therapeutic agents in a single package. By targeting the complex biological processes that drive the disease, this innovative approach represents a promising step toward next-generation therapies for chronic oral inflammation.